DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Information source: Pearl Therapeutics, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Obstructive Pulmonary Disease

Intervention: PT001 MDI (Drug); Tiotropium Bromide (Drug); PT001 Placebo MDI (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Pearl Therapeutics, Inc.

Official(s) and/or principal investigator(s):
Colin Reisner, MD, Study Director, Affiliation: Pearl Therapeutics, Inc.

Summary

The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.

Clinical Details

Official title: A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: FEV1 AUC0-12

Secondary outcome:

Peak change in FEV1

Time to onset of action

Peak change in Inspiratory Capacity (IC)

Detailed description: The primary objective of this study is to assess efficacy relative to placebo of GP MDI in subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the range of doses evaluated in this protocol. To this end, each dose of GP MDI will be compared to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.

Eligibility

Minimum age: 40 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed written informed consent

- 40 - 80 years of age

- Clinical history of COPD with airflow limitation that is not fully reversible

- Females of non-child bearing potential or females of child bearing potential with

negative pregnancy test; and acceptable contraceptive methods

- Current/former smokers with at least a 10 pack-year history of cigarette smoking

- A measured post- bronchodilator FEV1/FVC ratio of < or = 0. 70

- A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of

predicted normal values

- Able to change COPD treatment as required by protocol

Exclusion Criteria:

- Women who are pregnant or lactating

- Primary diagnosis of asthma

- Alpha-1 antitrypsin deficiency as the cause of COPD

- Active pulmonary diseases

- Prior lung volume reduction surgery

- Abnormal chest X-ray (or CT scan) not due to the presence of COPD

- Hospitalized due to poorly controlled COPD within 3 months of Screening

- Clinically significant medical conditions that preclude participation in the study

(e. g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)

- Cancer that has not been in complete remission for at least 5 years

- Treatment with investigational study drug or participation in another clinical trial

or study within the last 30 days or 5 half lives Other inclusion/exclusion criteria as defined in the protocol

Locations and Contacts

Pearl Investigative Site, Fullerton, California 92835, United States

Pearl Investigative Site, Clearwater, Florida 33765, United States

Pearl Investigative Site, Panama City, Florida 32405, United States

Pearl Investigative Site, Tampa, Florida 33603, United States

Pearl Investigative Site, Winter Park, Florida 32789, United States

Pearl Investigative Site, Charlotte, North Carolina 28207, United States

Pearl Investigative Site, Medford, Oregon 97504, United States

Pearl Investigative Site, Spartanburg, South Carolina 29303, United States

Pearl Investigative Site, Longview, Texas 75605, United States

Pearl Investigative Site, Richmond, Virginia 23225, United States

Additional Information

Starting date: March 2012
Last updated: November 14, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017